

12-04-03

16:18

From-CLARK & ELBING LLP

617-237-1558

T-186 P 001/004 F-846

RECEIVED
CENTRAL FAX CENTER

DEC 04 2003

Clark & Elbing LLP

101 Federal Street
Boston, MA 02110

Telephone 617-423-0200
Facsimile 617-428-7045
617-423-7046

Date: December 4, 2003

To: Examiner Anne Marie Falk
U.S. Patent and Trademark Office
Group Art Unit 1632

Facsimile No: (703) 872-9306

From: Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109
Customer No. 21559

Re: U.S. Serial No. 09/560,124
METHODS FOR THE IDENTIFICATION OF COMPOUNDS
FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Our Reference: 50122/002003

Pages: 4, Including Fax Cover Sheet

Message: Attachments:

Signed Declaration of Ralph Nixon

3 pages



NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

12-04-03

16:18

From-CLARK & ELBING LLP

617-237-1558

T-186

P.002/004

RECEIVED
CENTRAL FAX CENTER


DEC 04 2003

PATENT
ATTORNEY DOCKET NO. 50122/002003Certificate of Transmission by Facsimile: Date of Transmission: December 4, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being transmitted by facsimile to the Examiner listed below, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated above.

Guy E. Beardsley

Printed name of person transmitting facsimile



Signature of person transmitting facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|---|---------------|-----------------|
| Applicant: | Ralph A. Nixon et al. | Art Unit: | 1632 |
| Serial No.: | 09/560,124 | Examiner: | Anne-Marie Falk |
| Filed: | April 28, 2000 | Customer No.: | 21559 |
| Title: | METHODS FOR THE IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF RALPH NIXON, M.D., PH.D., UNDER 37 C.F.R. § 1.132
TRAVERSING GROUNDS OF REJECTION

Under 37 C.F.R. § 1.132, I declare:

1. I am a Professor in the departments of Psychiatry and Cell Biology, New York University School of Medicine, and Director of Research, Nathan S. Kline Institute for Psychiatric Research, and an inventor on the above-captioned patent application. I have been studying Alzheimer's Disease for since 1970 and I have published more than 160 papers in the field.

2. I have read and understood the Office Action dated April 9, 2003.

3. The experiments carried out in the Declaration filed on January 8, 2003, were carried out using methods that were standard in the art at the time the application was filed.

4. As described in the specification and in paragraph 5, I, along with the other named inventors, have directed and conducted experiments demonstrating that cells with enlarged endosomes also have increased endocytic pathway activity, which is characterized by specific endosomal changes (e.g., increased endosomal fusion, endosomal recycling, expression of MPR46, accumulation of lysosomal hydrolases in early endosomes, and accumulation of A β in early endosomes) indicative of cells that are destined to be diseased in patients having Alzheimer's disease. rab5 overexpressing cells *in vitro* and *in vivo* mimic the increased endocytic pathway activity that is observed in patients with early stage Alzheimer's disease. Such compounds are excellent potential therapeutics given that they are likely to be useful in treating patients at a time when patients are essentially asymptomatic.

5. We have found that stably transfected murine L cells that overexpressed rab5 showed enlarged endosomes, similar to those observed in neurons from individuals with sporadic Alzheimer's Disease. In addition, a cDNA encoding the GTP-hydrolysis deficient rab5 mutant Q79L (Stenmark et al., EMBO J. 13:1287-1296, 1994) was expressed in L cells. Expression of the rab5 Q79L mutant resulted in increased endocytosis and the fusion of early endosomes into large vacuoles. Confirming that rab5 expression led to abnormal activity of the endosomal pathway, we also demonstrated both increased uptake of fluid phase markers (FITC-dextran) and increased receptor mediated endocytosis (transferrin).

6. As described in paragraph 7, experts accept that the presence of enlarged endosomes correlates with other markers of endosomal change, including endosomal fusion as evidenced in Roberts et al. (J. Cell Science 112:3667-3675, 1999).

7. Roberts et al. (J. Cell Science 112:3667-3675, 1999, hereafter "Roberts") show that the presence of enlarged endosomes correlates with endosomal fusion in cultured cells overexpressing rab5. Roberts overexpressed either wild-type rab5 or rab5:Q79L, a constitutively active rab5 mutant, in CHO and BHK cells and observed that the cells formed enlarged cytoplasmic vesicles that exhibited the characteristics of early endosomes. Using time-lapse video microscopy, Roberts showed that the enlarged endosomes resulted from endosomal fusion (page 3667, left column, abstract). Regarding these results, Roberts states, "Time-lapse video microscopy shows the enlarged endosomes arise primarily by fusion of smaller vesicles. These fusion events occur mostly by a 'bridge' fusion mechanism in which the initial opening between vesicles does not expand; instead, membrane flows slowly and continuously from the smaller to the larger endosome in the fusing pair. . ."

8. In sum, we have shown and experts accept that cells having enlarged endosomes also exhibit increased endocytic pathway activity, which is characterized by specific endosomal changes (e.g., increased endosomal fusion, endosomal recycling, expression of MPR46, accumulation of lysosomal hydrolases in early endosomes, and accumulation of A β in early endosomes.)

9. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application of any patents issued thereon.

Date: 12/1/03

R. Ralph Nixon
Dr. Ralph Nixon